Induction Chemotherapy and Toripalimab Followed by Radiotherapy in Unresectable Laryngeal/Hypopharyngeal Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

April 7, 2021

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions
Laryngeal CancerHypopharyngeal Cancer
Interventions
DRUG

Toripalimab

"Induction chemotherapy TP regimen combined with Toripalimab for 3 cycles: Toripalimab 240mg d1, Paclitaxel 175mg/m2 d2,Cisplatin 25mg/m2 d2-4 q3w. Then a total dose of 70Gy in 35 fractions was administered, with concurrently weekly cisplatin (30mg/m2 qw).~At 3-6 weeks post-radiotherapy, maintenance Toripalimab was administered for 8 cycles (240mg d1 q3w, in total 8 cycles)."

Trial Locations (1)

200032

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER